Supreme Court Observation on Cancer Drug Pricing
The Supreme Court has criticised the huge disparity between the Maximum Retail Price (MRP) and the Price to Retailer (PTR) for several oncology medicines. In some cases the MRP is up to 1,000% higher than the PTR.
Key Developments
- Hospitals negotiate low PTRs from manufacturers and sell at the statutory MRP, pocketing the margin.
- Private hospitals force patients to buy drugs from on‑premise pharmacies, eliminating price competition.
- The NPPA in 2019 capped trade margins of 42 non‑schedule anti‑cancer drugs at 30%, leading to price drops of up to 91% for 526 brands.
- The Court suggested a uniform percentage markup across all drugs, coupled with a regressive margin that falls as drug price rises.
Important Facts
The 2013 Drug (Prices Control) Order fixes the ceiling price but leaves hospital margins unchecked. For example, if the NPPA calculates an average market price of ₹100, the ceiling becomes ₹116. A hospital can obtain the drug at a PTR of ₹50 and still bill ₹116, earning a ₹66 margin without breaching the ceiling.
Investigations by the Competition Commission have shown that on‑site pharmacy mandates prevent patients from shopping around, hurting affordable alternatives.
The Department of Pharmaceuticals highlighted that many cancer drug MRPs contain compressible margins, confirming the Court’s concerns.
Exam Relevance
This issue touches upon several GS papers:
- GS3 (Economy): drug pricing, market regulation, and the role of NPPA.
- GS1 (Polity): judicial activism of the Supreme Court in public health matters.
- GS4 (Ethics): ethical implications of profit‑driven pricing that jeopardises patient access.
Understanding the interplay between price control orders, regulatory agencies, and judicial interventions is essential for answering questions on health economics and governance.
Way Forward
To curb the exploitative margin:
- Introduce a fixed, regressive markup schedule for all drugs, ensuring lower percentages for high‑priced medicines.
- Extend the scope of the 2013 Drug (Prices Control) Order to cover hospital‑to‑patient mark‑ups.
- Mandate transparent pricing in hospital pharmacies and allow patients to purchase from external pharmacies.
- Strengthen monitoring by the NPPA and empower the Competition Commission to act against anti‑competitive pharmacy practices.
These steps would align drug pricing with public health goals, reduce financial burden on cancer patients, and restore market competition.